It is our mission to one day end the suffering caused by neurodegenerative diseases. Every day we strive for better therapies. We question the unquestioned, always in search of new solutions.
To stay up to date on Amylyx news, click subscribe.
Our Mission
Our Mission
Who we are
Amylyx is a global pharmaceutical company based in Cambridge, Massachusetts, that is dedicated to the discovery and development of potential treatments for neurodegenerative diseases. We pursue unconventional approaches through lasting collaborations with industry leaders, scientists, doctors, research organizations, and the communities impacted by these relentlessly progressive diseases.
Our Story
The journey started with a simple question. While studying neurodegenerative diseases at Brown University, Amylyx Co-CEO Josh Cohen wondered, “Why do neurons die?” It seemed like such an obvious starting point, yet the solution was nowhere to be found. Upon examining the available research, Josh and a classmate—Co-CEO Justin Klee—decided to pursue the question further, relentlessly looking for answers. After years of work, they eventually accumulated enough data to pursue next steps and begin their own original research. Since 2013, the partnership between Josh and Justin evolved and gave rise to Amylyx, a rapidly growing company with the same curiosity and resilience as the day the company began.
Our path to progress
See the strides we've made so far since we were founded in 2013. Click on the graphic below to enlarge.
Our origin story
Our Values
Be audacious
People living with neurodegenerative diseases are our true north; we envision new possibilities, boldly seek untried approaches, and fearlessly innovate for them.
Be curious
By asking the right questions, listening, and learning, we thrive in a culture of continuous improvement, driven by generously sharing knowledge, making each of us, and the company, better.
Be engaged
We can only understand someone's needs when we understand their journey. By deeply engaging with the neurodegenerative disease community and their care providers, we know what’s needed.
Be accountable
People living with neurodegenerative diseases always come first. There is no time to wait, and we have a responsibility to turn our most promising ideas into urgent action on their behalf.
Be authentic
When we genuinely care about the work we do and the people with whom we work, we make Amylyx a place where possibility could one day turn into reality.
Driven by People
“« I feel like Amylyx is a very different company than most that I work with and truly seems like a company that cares, with a big heart, but further than that is they have a fierceness in them and they’re not going to back down from so many of the obstacles that people living with ALS have been facing.” »
Sandy, Person with ALS
“« When you're diagnosed with ALS [amyotrophic lateral sclerosis], you're no longer on the human clock, you're on the ALS clock. Every passing day is a lifetime to an ALS patient, and ALS patients don't have time to wait.” »
Cali, ALS caregiver
“« You require help, that in the years prior, you never needed — where people have to change their lifestyle, to make your lifestyle. So, it doesn't just affect you, it affects the ones around you.” »
Greg, Person living with ALS
Latest News
Next
An error has occurred. Please refresh the page and retry.
Built on Connections
We are all united in the fight against neurodegenerative diseases - true collaboration can change the course of a thought or an idea, or even the development of a therapy. Through strategic collaborations, participant-centric clinical trial design, and the sharing of ideas with open outreach, we can make a lasting impact in the neurodegenerative disease community.
People With Neurodegenerative Diseases
Be the change
Be the change
We've made some great strides in a short amount of time, but the work has just begun. If you'd like to join us in our mission, you can learn more about our culture and open positions below.